Glucose-6-Phosphate Dehydrogenase Activity and Protein Oxidative Modification in Patients with Type 2 Diabetes Mellitus

Table 1

The clinical and laboratory characteristics of the participants.

Parameter	Control (𝑛=20)	Diabetics (𝑛=40)
Age (years)	58±7.1	57±7
♂/♀ ratio	8 : 12	15 : 25
Medications	—	Oral hypoglycemic drugs
BMI (kg/m^2)	23.9±2.1 (8.4)	23±1.7 (7.2)
FBG (mg/dL)	101±10.8 (10.7)	274±50^∗∗∗ (18.4)
TC (mg/dL)	185±13 (7.1)	238.5±62.4^∗∗ (26.1)
HDL (mg/dL)	39±3.8 (10.1)	30.5±7.2^∗∗ (23.6)
LDL (mg/dL)	183±13.7 (7.5)	229±40^∗ (17.4)
Triglyceride (mg/dL)	166±32 (19.5)	176.5±57 (32.5)
HbA1c (%)	5.8±0.5 (8.68)	9.9±0.96^∗∗∗ (9.7)
G6PD activity (U/gHb)	8.1±0.7 (8.9)	6.7±0.76^∗∗∗ (11.4)
Protein carbonyl (nmol/mg protein)	3.2±0.54 (16.7)	14.5±2.14^∗∗∗ (14.8)
Total thiol (μmol/mL)	325±33 (10.3)	201±18^∗∗∗ (9.1)

Data were represented as mean ± SD (CV %). FBG: fasting blood glucose; TC: total cholesterol; HDL: high density lipoprotein; LDL: low density lipoprotein; ^∗∗∗𝑃<0.001, ^∗∗𝑃<0.01, ^∗𝑃<0.05.